| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802287701018 | 228770101 | LYO-DROL PS.INJ.SOL 40MG/VIAL BT x 1 VIAL + 1 AMP x 1ML SOLVENT x 1ML SOLVENT | 0.87 | 0.91 | 1.25 |
| 05/2018 | 2802287702015 | 228770201 | LYO-DROL PS.INJ.SOL 125MG/VIAL BT x 1 VIAL + 1 AMP x 2 ML SOLVENT x 2 ML SOLVENT | 1.25 | 1.31 | 1.80 |
| 05/2018 | 2802287703012 | 228770301 | LYO-DROL PS.INJ.SOL 500MG/VIAL BT x 1 VIAL +1 VIAL x 8 ML SOLVENT x 8 ML SOLVENT | 3.32 | 3.48 | 4.79 |
Adjunctive therapy for short-term administration in rheumatoid arthritis.
Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
LD<sub>50</sub>=2000 mg/kg (orally in rat)
Oral bioavailability 80-99%
1-3 hours